A Pharmaceutical Cannabidiol Company

A leader in the production of pharmaceutical cannabidiol

and the development of innovative cannabidiol medicines

for heart disease

Pharmaceutical CBD

Developing CardiolRxTM for the rapidly growing medicinal cannabinoids market.

Learn more

Heart Failure

Committed to conquering a serious condition that affects more than 26 million people globally.

Learn more

Acute Myocarditis

Cardiol is planning an international clinical study of acute myocarditis, a condition caused by inflammation in heart tissue.

Learn more

Innovative Science and Technology to Improve Quality of Life

Research & Development

Latest News

All news

December 03, 2019

Cardiol Therapeutics Appoints Former GW Pharmaceuticals Executive Colin Stott to its Board of Directors

November 25, 2019

Cardiol Therapeutics comments on the Descheduling of Purisys Cannabinoid Ingredients by U.S. Drug Enforcement Agency

November 19, 2019

Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx™100

Email Updates

Sign up for our Cardiol Therapeutics newsletter to stay up to date with our most recent news, industry updates and press releases.

By submitting this form, you are consenting to receive marketing emails from: Cardiol Therapeutics Inc., 2275 Upper Middle Road East, Suite 101, Oakville, Ontario, L6H 0C3, CA, http://cardiolrx.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Mailchimp. Our Privacy Policy.

No, thanks

TSX: CRDL OTCQX: CRTPF

 

© 2019 Cardiol Therapeutics Inc. All rights reserved.      Terms of Use      Privacy Policy